Rosen Discusses FDA's Plan to Conduct More Extensive Studies of Generic Blood Pressure Medications
May 6, 2014
Bloomberg
Partner David Rosen was quoted in a Bloomberg article published on May 6, 2014, titled “Blood-Pressure Drug With Thousands of Complaints Draws FDA Test.” The article discussed the U.S. Food and Drug Administration’s plan to conduct more extensive studies of generic blood pressure medications after receiving numerous complaints of ineffectiveness and troublesome side effects. Rosen was quoted saying, “It’s an important issue and we want to make sure these products perform in the way they’re supposed to perform.”
People
Related News
June 25, 2025
In the News
Jocelyn Lavallo Explores Nuclear's Emerging Role in Project Finance
Foley & Lardner LLP partner Jocelyn Lavallo examined the increasing relevance of advanced nuclear technologies in the evolving clean energy landscape in her Environment+Energy Leader article, "Nuclear’s Emerging Role in Project Finance: A Cross-Technology Perspective."
June 25, 2025
In the News
Kyle Faget Comments on AI, User Fees Ahead of MDUFA Negotiations
Foley & Lardner LLP partner Kyle Faget weighed in on the role of user fees and artificial intelligence as stakeholders prepare for the next Medical Device User Fee Amendments (MDUFA) reauthorization in the Medtech Insight article, "Will Kennedy And Makary Come To Terms On User Fees During Next Round Of MDUFA Negotiations?"
June 25, 2025
In the News
Foley Chairman Daljit Doogal Talks Strategic Growth, Expansion into Three New Markets on Podcast
Foley & Lardner LLP Chairman and CEO Daljit Doogal joined an episode of the On the Merits podcast with Bloomberg Law to tell the story of Foley’s successful strategic expansion into three emerging legal markets within the last four years.